DARZALEX (daratumumab)
ANTINEOPLASTIC - ANTI-CD38 MONOCLONAL ANTIBODY · MULTIPLE MYELOMA
JANSSEN BIOTECH, Inc.
Drug class
Antineoplastic - Anti-CD38 Monoclonal Antibody
Antineoplastic anti-CD38 monoclonal antibodies are targeted immunotherapeutic agents designed to selectively bind the CD38 transmembrane glycoprotein abundantly expressed on malignant plasma cells. Read more about Antineoplastic - Anti-CD38 Monoclonal Antibody
4 drugs in this class 2 manufacturers
Drugs in Antineoplastic - Anti-CD38 Monoclonal Antibody
SARCLISA (isatuximab-irfc)
ANTINEOPLASTIC - ANTI-CD38 MONOCLONAL ANTIBODY · MULTIPLE MYELOMA
Sanofi-Aventis U.S.
DARZALEX FASPRO (daratumumab-hyaluronidase-fihj)
ANTINEOPLASTIC - ANTI-CD38 MONOCLONAL ANTIBODY · MULTIPLE MYELOMA ·+2
JANSSEN BIOTECH, Inc.
SARCLISA ESCENA (isatuximab-irfc)
ANTINEOPLASTIC - ANTI-CD38 MONOCLONAL ANTIBODY · MULTIPLE MYELOMA
Sanofi-Aventis U.S.
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Anti-CD38 Monoclonal Antibody preselected. Add indication or manufacturer filters there.
Antineoplastic anti-CD38 monoclonal antibodies are targeted immunotherapeutic agents designed to selectively bind the CD38 transmembrane glycoprotein abundantly expressed on malignant plasma cells.
Upon binding, these antibodies promote tumor cell clearance through multimodal immune-mediated pathways, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis.
Clinically, members of this drug class—such as daratumumab and isatuximab—serve as cornerstones in the treatment of newly diagnosed and relapsed or refractory multiple myeloma, and are also employed in related plasma cell disorders such as light chain amyloidosis.
-
cancer.gov
Antineoplastic anti-CD38 monoclonal antibodies are targeted immunotherapeutic agents designed to selectively bind the CD38 transmembrane glycoprotein abundantly expressed on malignant plasma cells Clinically, members of this drug class—such as daratumumab and isatuximab—serve as cornerstones in the treatment of newly diagnosed and relapsed or refractory multiple myeloma, and are also employed in related plasma cell disorders such as light chain amyloidosis
-
ashpublications.org
Antineoplastic anti-CD38 monoclonal antibodies are targeted immunotherapeutic agents designed to selectively bind the CD38 transmembrane glycoprotein abundantly expressed on malignant plasma cells Upon binding, these antibodies promote tumor cell clearance through multimodal immune-mediated pathways, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis Clinically, members of this drug cl...
-
cancer.gov
Upon binding, these antibodies promote tumor cell clearance through multimodal immune-mediated pathways, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis
-
cancer.gov
Upon binding, these antibodies promote tumor cell clearance through multimodal immune-mediated pathways, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.